Get the Stockscreener App
0.191
3.30%
0.0061
Pre-market:
.19
-0.001
-0.52%
Ernexa Therapeutics Inc stock is traded at $0.191, with a volume of 97,985.
It is up +3.30% in the last 24 hours and down -37.15% over the past month.
See More
Previous Close:
$0.1849
Open:
$0.19
24h Volume:
97,985
Relative Volume:
0.01
Market Cap:
$9.66M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.023
EPS:
-8.31
Net Cash Flow:
$-17.32M
1W Performance:
-16.85%
1M Performance:
-37.15%
6M Performance:
-80.83%
1Y Performance:
-91.87%
1-Day Range:
$0.18
$0.1958
1-Week Range:
$0.1601
$0.261
52-Week Range:
$0.1601
$2.625
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(212) 582-1199
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
0.191 | 9.66M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics By Investing.com - Investing.com Australia
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics - Investing.com
Eterna Therapeutics Changes Name to Ernexa Therapeutics to - GlobeNewswire
Major Pivot: Eterna Becomes Ernexa, Unveils New Cancer and Autoimmune Disease Strategy - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - MarketBeat
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - MarketBeat
Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) Declares $0.09 Monthly Dividend - MarketBeat
Eterna Therapeutics sets annual meeting date, opens nominations - MSN
Better AI Stock: SoundHound AI vs. Broadcom - The Globe and Mail
Eterna Therapeutics Hosts Successful Inaugural Meeting with - GlobeNewswire
Can Eterna's Expert-Backed Cell Therapy Breakthrough Revolutionize Ovarian Cancer Treatment? - StockTitan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Eterna Therapeutics (NASDAQ:ERNA) & Galecto (NASDAQ:GLTO) Head to Head Comparison - Defense World
Eterna Therapeutics Inc (ERNA)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - Defense World
Ratio Examination: Eterna Therapeutics Inc (ERNA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
ERNA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Eterna Therapeutics Inc (ERNA) is a good investment, but the stock may be undervalued - US Post News
Contrasting Eterna Therapeutics (NASDAQ:ERNA) and Anixa Biosciences (NASDAQ:ANIX) - Defense World
Market Insight: Eterna Therapeutics Inc (ERNA)’s Notable Drop, Closing at 0.36 - The Dwinnex
Eterna Therapeutics expands scientific board with oncology experts - MSN
Eterna Therapeutics’ Shares Surge After Promising Preclinical Results for ERNA-101 Cell Therapy - HPBL
Eterna Therapeutics expands scientific board with oncology experts By Investing.com - Investing.com Canada
Eterna Therapeutics Announces Expansion of Scientific Advisory Board - GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
3 Penny Stocks to Watch Now, 1/16/25 - TipRanks
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):